Imvax: advancing a new approach to personalized cancer immunotherapy

Imvax pipeline: focused on solid tumors
- Glioblastoma
- Endometrial cancer
- Hepatocellular carcinoma
- Urothelial cancer
- Ovarian cancer

<table>
<thead>
<tr>
<th>IND enabling</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGV-001</td>
<td>IEC-001</td>
<td>IHC-001</td>
<td>IUC-001</td>
</tr>
</tbody>
</table>

Imvax’s Goldspire™ platform fits seamlessly into standard-of-care treatment for newly diagnosed glioblastoma (ndGBM)

Phase 2b study of IGV-001 in ndGBM is enrolling (NCT04485949)

Advantages of the Goldspire™ platform
- Captures full immune-related signals
- Avoids off-target effects
- Activates broad immune response
- Fits into standard of care
- Overnight tissue processing

Immune response attacks tumors on many fronts

1. IMMUNOGENIC CELL DEATH
   - IGV-001 plus radiation causes tumor cell death in the chambers that are implanted, leading to immune response

2. APCs ACTIVATED
   - Antigens and IGV-001 antisense oligonucleotide pass through the chamber’s small pores and are picked up by cells of the immune system (APCs)

3. T CELLS PRIMED
   - Activated APCs reach sentinel lymph nodes and prime local T cells against the tumor

4. T CELLS SLOW DOWN CANCER GROWTH AND KILL TUMOR CELLS
   - The T cells find the tumor and cause tumor cell death, getting the immune system ready to guard against future tumors

APC, antigen-presenting cell; IND, investigational new drug.

© Copyright 2023 Imvax, Inc. All rights reserved.